Trial Profile
A pilot study to assess immunogenicity of the prime-boost revaccination strategy using 13-Valent Pneumococcal Conjugate Vaccine followed by 23-Valent Pneumococcal Polysaccharide Vaccine vaccination 8 weeks later in 24 patients with Rheumatoid Arthritis (RA) treated by Methotrexate (MTX) and anti-TNF
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 12 Dec 2017 New trial record
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting